IRIS
CAZZOLA, MARIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 50.662
EU - Europa 4.463
AS - Asia 2.181
SA - Sud America 36
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 27
AF - Africa 6
Totale 57.403
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 50.617
CN - Cina 1.251
UA - Ucraina 961
IE - Irlanda 766
DE - Germania 606
KR - Corea 549
IT - Italia 407
PL - Polonia 404
FR - Francia 364
GB - Regno Unito 266
SG - Singapore 229
FI - Finlandia 228
SE - Svezia 185
RU - Federazione Russa 146
CA - Canada 34
NL - Olanda 31
JP - Giappone 30
IN - India 22
BE - Belgio 21
AU - Australia 17
A2 - ???statistics.table.value.countryCode.A2??? 15
ES - Italia 15
CL - Cile 14
EU - Europa 12
VN - Vietnam 12
GR - Grecia 11
MY - Malesia 11
NZ - Nuova Zelanda 11
BR - Brasile 10
HK - Hong Kong 9
CH - Svizzera 7
IL - Israele 7
IR - Iran 7
TR - Turchia 7
CZ - Repubblica Ceca 6
MX - Messico 6
RO - Romania 6
BD - Bangladesh 5
EC - Ecuador 5
EG - Egitto 5
ID - Indonesia 5
NO - Norvegia 5
PH - Filippine 5
PT - Portogallo 5
AT - Austria 4
IQ - Iraq 4
MK - Macedonia 4
AR - Argentina 3
DK - Danimarca 3
HU - Ungheria 3
JO - Giordania 3
KH - Cambogia 3
PE - Perù 3
SA - Arabia Saudita 3
TW - Taiwan 3
DM - Dominica 2
EE - Estonia 2
GT - Guatemala 2
LK - Sri Lanka 2
MD - Moldavia 2
NP - Nepal 2
PK - Pakistan 2
TH - Thailandia 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CO - Colombia 1
CR - Costa Rica 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LT - Lituania 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
SC - Seychelles 1
Totale 57.403
Salva come PNG Salva come JPEG
Città #
Woodbridge 12.783
Wilmington 12.541
Houston 12.252
Fairfield 2.728
Ann Arbor 1.724
Ashburn 1.183
Seattle 1.141
Chandler 922
Cambridge 888
Jacksonville 830
Dublin 686
Medford 528
Dearborn 461
Hangzhou 422
Kraków 403
Beijing 367
Lawrence 240
New York 201
Zhengzhou 164
Singapore 144
San Diego 135
Rome 127
Menlo Park 120
Mülheim 83
Moscow 69
Redwood City 57
Norwalk 55
Milan 50
Mountain View 46
Boardman 42
London 39
Chicago 37
San Mateo 37
Shanghai 37
Detroit 36
Helsinki 34
Verona 33
Hefei 32
Nanjing 32
University Park 31
Palo Alto 28
Falls Church 27
Kunming 26
Guangzhou 24
Jinan 22
Saint Petersburg 22
Toronto 22
Brussels 20
Redmond 17
San Francisco 15
San Jose 13
Hounslow 12
Phoenix 12
Chengdu 10
Kilburn 10
La Veta 10
Los Angeles 10
Seoul 10
Shenyang 10
Wuhan 10
Fuzhou 9
Nuremberg 9
Hanoi 8
Indiana 8
Nanchang 8
Prescot 8
Athens 7
Washington 7
Giv‘atayim 6
Kuala Lumpur 6
Naples 6
Olomouc 6
São Paulo 6
Canberra 5
Caserta 5
Groningen 5
Hamilton 5
Hebei 5
Jiaxing 5
Ottawa 5
Simi Valley 5
Taizhou 5
Tokyo 5
Xian 5
Auburn Hills 4
Berlin 4
Cagliari 4
Council Bluffs 4
Dong Ket 4
Durham 4
Hong Kong 4
Köln 4
Lappeenranta 4
Munich 4
Ningbo 4
Pune 4
San Prisco 4
Secaucus 4
Acton 3
Amsterdam 3
Totale 52.281
Salva come PNG Salva come JPEG
Nome #
An update on the pharmacotherapeutic management of lower respiratory tract infections 489
Asthma and COPD in an Italian adult population: Role of BMI considering the smoking habit 451
Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells 447
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis 446
Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis 445
Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. 444
Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma? 444
Interaction between corticosteroids and muscarinic antagonists in human airways 436
Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation 435
Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD 432
An unusual outbreak of nontuberculous mycobacteria in hospital respiratory wards: Association with nontuberculous mycobacterial colonization of hospital water supply network 429
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab 425
A systems medicine clinical platform for understanding and managing non- communicable diseases 423
Glucagon-like peptide 1 receptor: A novel pharmacological target for treating human bronchial hyperresponsiveness 421
Optimizing drug delivery in COPD: The role of inhaler devices 419
Treatment options for moderate-to-very severe chronic obstructive pulmonary disease 417
Withdrawal of inhaled corticosteroids in COPD: A meta-analysis 416
Asthma and comorbid medical illness. 414
Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease 414
Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. 413
A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD 413
Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update 412
Tiotropium formulations and safety: a network meta-analysis 412
High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. 406
LABA/LAMA combination in copd: A meta-analysis on the duration of treatment 404
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases 403
Role of muscarinic antagonists in asthma therapy 402
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis 400
Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease 399
Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease 399
Bronchodilator therapy for chronic cough 398
Asthma and comorbid medical illness 391
Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi 390
The prevalence of asthma and COPD in Italy: a practice-based study 389
Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease: A point of view 388
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease 388
Metabolic syndrome and risk of pulmonary involvement 386
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease 385
The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils 385
The Challenges of Precision Medicine in COPD 385
New Treatments for COPD in the Elderly 383
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways 383
Airflow obstruction: Is it asthma or is it COPD? 383
Bacterial lysates as a potentially effective approach in preventing acute exacerbation of COPD. 380
Umeclidinium for the treatment of chronic obstructive pulmonary disease 379
Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study 378
Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi 377
Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study 376
Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi 376
The effect of indacaterol during an acute exacerbation of COPD 376
Do we really need asthma-chronic obstructive pulmonary disease overlap syndrome? 372
Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008 371
Translational study searching for synergy between glycopyrronium and indacaterol 371
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease 370
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi 370
Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients 368
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone 367
Comorbidities of asthma 367
An overview of the current management of chronic obstructive pulmonary disease: can we go beyond the GOLD recommendations? 367
Influence of ethnicity on response to asthma drugs 365
Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD 363
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study 361
Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi 360
null 359
Chronic treatment with indacaterol and airway response to salbutamol in stable COPD 358
Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond 356
Indacaterol for the treatment of chronic obstructive pulmonary disease 355
Biomarkers of lung damage associated with tobacco smoke in induced sputum 354
Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives 353
Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside 352
The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections 352
Defining Phenotypes in COPD: An Aid to Personalized Healthcare 351
Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis 351
Pharmacological modulation of beta-adrenoceptor function in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure 349
A pilot comparison of helium dilution and plethysmographic lung volumes to assess the impact of a long-acting bronchodilator on lung hyperinflation in COPD 347
Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease 346
Diabetes mellitus among outpatients with COPD attending a university hospital. 344
Treating systemic effects of COPD 342
Cardiovascular disease in patients with COPD 342
LABA/LAMA combinations instead of LABA/ICS combinations may prevent or delay exacerbations of COPD in some patients 340
Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics 340
The clinical use of regenerative therapy in COPD 339
β2-Agonist Therapy in Lung Disease 337
Adherence to COPD treatment: Myth and reality 331
Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis 331
Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways 329
Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism 327
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease 322
In stable COPD, long-acting muscarinic antagonist plus long-acting beta-agonists resulted in less exacerbations, pneumonia and larger improvement in FEV 1 than long-acting beta-agonists plus inhaled corticosteroids 321
Biomarkers in COPD 319
Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus 319
Dual bronchodilation and exacerbations of COPD 319
Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis 317
Long‑term management of patients with chronic obstructive pulmonary disease who undergo percutaneous coronary intervention still needs to be dramatically improved 317
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma 317
Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease 316
Inhaled corticosteroids for chronic obstructive pulmonary disease 315
An update on bronchodilators in Phase I and II clinical trials 314
Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold? 314
Fluticasone furoate/vilanterol combination for the treatment of asthma and COPD 311
Totale 37.564
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.771
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.771
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202015.789 0 1.302 1.075 1.836 1.628 1.974 1.578 1.662 1.531 1.268 884 1.051
2020/20219.039 908 1.090 953 1.035 872 830 1.237 831 314 297 485 187
2021/20222.318 153 225 72 55 77 259 145 109 133 271 159 660
2022/20232.704 350 152 54 322 244 668 251 172 237 19 163 72
2023/2024915 198 28 69 12 85 214 61 43 16 35 17 137
2024/2025261 227 34 0 0 0 0 0 0 0 0 0 0
Totale 58.011